Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma

Clinical Lung Cancer

Volumn 16, Issue 5, 2015, Pages e25-e35

  Lin, Cheng ^a   Chen, Xiong ^a   Li, Meifang ^b   Liu, Jingnan ^a   Qi, Xingfeng ^c   Yang, Wenting ^c   Zhang, Hairong ^a   Cai, Zhongfu ^d   Dai, Yun ^e   Ouyang, Xuenong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^c FUZHOU GENERAL HOSPITAL   (China)

^d The 180th Hospital of People's Liberation Army   (China)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

EGFR mutation; EGFR TKI therapy; Immunohistochemistry; Lung adenocarcinoma; PD L1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84938491216     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2015.02.002     Document Type: Article

References (60)

1. D.H. Johnson, J.H. Schiller, and P.A. Bunn Jr. Recent clinical advances in lung cancer management J Clin Oncol 32 2014 973 982
2. H.S. Shim, H. da Lee, E.J. Park, and S.H. Kim Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification Arch Pathol Lab Med 135 2011 1329 1334
3. H. Shigematsu, L. Lin, T. Takahashi, and et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
4. L.V. Sequist, D.W. Bell, T.J. Lynch, and D.A. Haber Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer J Clin Oncol 25 2007 587 595
5. V.L. Keedy, S. Temin, M.R. Somerfield, and et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy J Clin Oncol 29 2011 2121 2127
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer V2.2012. Available at: http://www.nccn.org/professionals/physiciangls/PDF/nscl.pdf. Accessed October 1, 2014.
7. K. Ohashi, Y.E. Maruvka, F. Michor, and W. Pao Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease J Clin Oncol 31 2013 1070 1080
8. W. Pao, V.A. Miller, K.A. Politi, and et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 2005 e73
9. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
10. L. Zitvogel, and G. Kroemer Targeting PD-1/PD-L1 interactions for cancer immunotherapy Oncoimmunology 1 2012 1223 1225
11. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 1992 3887 3895
12. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
13. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
14. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
15. R.D. Harvey Immunologic and clinical effects of targeting PD-1 in lung cancer Clin Pharmacol Ther 96 2014 214 223
16. Y. Ohigashi, M. Sho, Y. Yamada, and et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 2005 2947 2953
17. R.H. Thompson, S.M. Kuntz, B.C. Leibovich, and et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 66 2006 3381 3385
18. Q. Gao, X.Y. Wang, S.J. Qiu, and et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 2009 971 979
19. T. Nomi, M. Sho, T. Akahori, and et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin Cancer Res 13 2007 2151 2157
20. M. Song, D. Chen, B. Lu, and et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer PLoS One 8 2013 e65821
21. C. Wu, Y. Zhu, J. Jiang, J. Zhao, X.G. Zhang, and N. Xu Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance Acta Histochem 108 2006 19 24
22. Y.B. Chen, C.Y. Mu, and J.A. Huang Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study Tumori 98 2012 751 755
23. E.A. Akbay, S. Koyama, J. Carretero, and et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discov 3 2013 1355 1363
24. A.J. Rech, and R.H. Vonderheide Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment Cancer Discov 3 2013 1330 1332
25. C.R. Newton, A. Graham, L.E. Heptinstall, and et al. Analysis of any point mutation in DNA: the amplification refractory mutation system (ARMS) Nucleic Acids Res 17 1989 2503 2516
26. D. Whitcombe, J. Theaker, S.P. Guy, T. Brown, and S. Little Detection of PCR products using self-probing amplicons and fluorescence Nat Biotechnol 17 1999 804 807
27. J.M. Taube, A.P. Klein, J.R. Brahmer, and et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy Clin Cancer Res 20 2014 5064 5074
28. S. Salvi, V. Fontana, S. Boccardo, and et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer Cancer Immunol Immunother 61 2012 1463 1472
29. C.Y. Mu, J.A. Huang, Y. Chen, and et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
30. E.A. Eisenhauer, P. Therasse, J. Bogaerts, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
31. A. Kataki, P. Scheid, M. Piet, and et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression J Lab Clin Med 140 2002 320 328
32. N.A. Rizvi, E.B. Garon, A. Patnaik, and et al. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC) J Clin Oncol 32 suppl 2014 5s abstract 8007
33. E.B. Garon, N.B. Leighl, N.A. Rizvi, and et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) J Clin Oncol 32 suppl 2014 5s abstract 8020
34. N.A. Rizvi, L.Q.M. Chow, L.Y. Dirix, and et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) J Clin Oncol 32 suppl 2014 5s abstract TPS8123
35. D.R. Spigel, S.N. Gettinger, L. Horn, and et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 31 suppl 2013 abstract 8008
36. N.A. Rizvi, L.Q.M. Chow, H. Borghaei, and et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC J Clin Oncol 32 suppl 2014 5s abstract 8022
37. C. Xu, C.M. Fillmore, S. Koyama, and et al. Loss of Lkb1 and PTEN leads to lung squamous cell carcinoma with elevated PD-L1 expression Cancer Cell 25 2014 590 604
38. K. Azuma, K. Ota, A. Kawahara, and et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer Ann Oncol 25 2014 1935 1940
39. A. D'Incecco, M. Andreozzi, V. Ludovini, and et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients Br J Cancer 112 2015 95 102
40. C.Y. Yang, M.W. Lin, Y.L. Chang, C.T. Wu, and P.C. Yang Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes Eur J Cancer 50 2014 1361 1369
41. J.M. Boland, E.D. Kwon, S.M. Harrington, and et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung Clin Lung Cancer 14 2013 157 163
42. V. Velcheti, D.L. Rimm, and K.A. Schalper Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) J Thorac Oncol 8 2013 803 805
43. S.L. Topalian, C.G. Drake, and D.M. Pardoll Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity Curr Opin Immunol 24 2012 207 212
44. H. Dong, G. Zhu, K. Tamada, and L. Chen B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 5 1999 1365 1369
45. R. Hino, K. Kabashima, Y. Kato, and et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma Cancer 116 2010 1757 1766
46. Y. Zhang, L. Wang, Y. Li, and et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma Onco Targets Ther 7 2014 567 573
47. V. Velcheti, K.A. Schalper, D.E. Carvajal, and et al. Programmed death ligand-1 expression in non-small cell lung cancer Lab Invest 94 2014 107 116
48. C. Zhou, Y.L. Wu, G. Chen, and et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
49. T.J. Lynch, D.W. Bell, R. Sordella, and et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
50. M. Fukuoka, Y.L. Wu, S. Thongprasert, and et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
51. R. Rosell, E. Carcereny, R. Gervais, and et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
52. S. Spranger, R.M. Spaapen, Y. Zha, and et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells Sci Transl Med 5 2013 200ra116
53. S. Park, Z. Jiang, E.D. Mortenson, and et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity Cancer Cell 18 2010 160 170
54. K. Araki, A.P. Turner, V.O. Shaffer, and et al. mTOR regulates memory CD8 T-cell differentiation Nature 460 2009 108 112
55. M. Dougan, S. Dougan, J. Slisz, and et al. IAP inhibitors enhance co-stimulation to promote tumor immunity J Exp Med 207 2010 2195 2206
56. J.M. Taube, R.A. Anders, G.D. Young, and et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape Sci Transl Med 4 2012 127ra137
57. J. Konishi, K. Yamazaki, M. Azuma, I. Kinoshita, H. Dosaka-Akita, and M. Nishimura B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 10 2004 5094 5100
58. B.A. Inman, T.J. Sebo, X. Frigola, and et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression Cancer 109 2007 1499 1505
59. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer Clin Cancer Res 19 2013 1021 1034
60. Y. Zhang, S. Huang, D. Gong, Y. Qin, and Q. Shen Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer Cell Mol Immunol 7 2010 389 395